528 related articles for article (PubMed ID: 22264265)
21. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.
Ning Y; Zhang W; Hanna DL; Yang D; Okazaki S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; El-Khoueiry A; Lenz HJ
Pharmacogenomics J; 2018 Jan; 18(1):29-34. PubMed ID: 27503579
[TBL] [Abstract][Full Text] [Related]
23. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of
Strati A; Nikolaou M; Georgoulias V; Lianidou ES
Cells; 2019 Jun; 8(7):. PubMed ID: 31261917
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
[TBL] [Abstract][Full Text] [Related]
27. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells.
Bidard FC; Vincent-Salomon A; Sigal-Zafrani B; Diéras V; Mathiot C; Mignot L; Thiery JP; Sastre-Garau X; Pierga JY
Ann Oncol; 2008 Mar; 19(3):496-500. PubMed ID: 18187488
[TBL] [Abstract][Full Text] [Related]
28. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
29. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
30. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer.
Banys M; Krawczyk N; Becker S; Jakubowska J; Staebler A; Wallwiener D; Fehm T; Rothmund R
Breast Cancer Res Treat; 2012 Feb; 132(1):121-9. PubMed ID: 21562707
[TBL] [Abstract][Full Text] [Related]
31. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
[TBL] [Abstract][Full Text] [Related]
32. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
[TBL] [Abstract][Full Text] [Related]
33. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.
Hinz S; Hendricks A; Wittig A; Schafmayer C; Tepel J; Kalthoff H; Becker T; Röder C
BMC Cancer; 2017 Jan; 17(1):53. PubMed ID: 28086834
[TBL] [Abstract][Full Text] [Related]
34. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients.
Schindlbeck C; Andergassen U; Hofmann S; Jückstock J; Jeschke U; Sommer H; Friese K; Janni W; Rack B
J Cancer Res Clin Oncol; 2013 Jun; 139(6):1055-62. PubMed ID: 23525580
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
[TBL] [Abstract][Full Text] [Related]
36. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
37. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
Akkiprik M; Koca S; Uğurlu MÜ; Ekren R; Peker Eyüboğlu İ; Alan Ö; Erzik C; Güllü Amuran G; Telli TA; Güllüoğlu MB; Sezerman U; Yumuk PF
Clin Breast Cancer; 2020 Aug; 20(4):332-343.e3. PubMed ID: 32201164
[TBL] [Abstract][Full Text] [Related]
38. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
[TBL] [Abstract][Full Text] [Related]
40. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]